Advertisement


Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy

2019 ASCO Annual Meeting

Advertisement

Alok A. Khorana, MD, of the Cleveland Clinic, and Hedy L. Kindler, MD, of The University of Chicago, discuss phase III findings on olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with metastatic pancreatic cancer and a germline BRCA mutation (Abstract LBA4).



Related Videos

Kidney Cancer

Leonard J. Appleman, MD, PhD, on Metastatic Renal Cell Carcinoma: Pazopanib vs Placebo After Metastasectomy

Leonard J. Appleman, MD, PhD, of UPMC Hillman Cancer Center, discusses phase III trial findings that showed a trend toward worse survival with pazopanib in patients with metastatic kidney cancer who exhibited no evidence of disease following metastasectomy (Abstract 4502).

Sarcoma
Immunotherapy

William D. Tap, MD, on Soft-Tissue Sarcomas: ANNOUNCE Trial on Doxorubicin and Olaratumab

William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, discusses negative study findings on doxorubicin plus olaratumab vs doxorubicin plus placebo, which showed no difference in overall survival between the two treatments in patients with advanced soft-tissue sarcomas. The manufacturer is currently withdrawing olaratumab from the global market (Abstract LBA3).

 

Multiple Myeloma
Immunotherapy

Paul G. Richardson, MD, on Relapsed or Refractory Multiple Myeloma: Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses findings from the phase III ICARIA-MM trial showing that isatuximab, pomalidomide, and low-dose dexamethasone significantly improved progression-free survival and overall response vs pomalidomide and dexamethasone (Abstract 8004).

 

Breast Cancer
Immunotherapy

Hope S. Rugo, MD, and Matteo Lambertini, MD, PhD, on the SOPHIA Trial in HER2-Positive Metastatic Breast Cancer: Chemotherapy Plus Margetuximab vs Trastuzumab

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings from the SOPHIA trial on margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer after prior anti-HER2 therapies (Abstract 1000).

Solid Tumors

Brian C. Baumann, MD, on Locally Advanced Cancer: Proton vs Photon Therapy

Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings that showed, for adults with locally advanced cancer across five different disease sites, proton chemoradiotherapy was associated with significantly reduced acute adverse events, with no difference in disease-free or overall survival (Abstract 6521).

Advertisement

Advertisement




Advertisement